Genome Medicine (Sep 2017)
Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic
- Dianne Nicol,
- Lisa Eckstein,
- Michael Morrison,
- Jacob S. Sherkow,
- Margaret Otlowski,
- Tess Whitton,
- Tania Bubela,
- Kathryn P. Burdon,
- Don Chalmers,
- Sarah Chan,
- Jac Charlesworth,
- Christine Critchley,
- Merlin Crossley,
- Sheryl de Lacey,
- Joanne L. Dickinson,
- Alex W. Hewitt,
- Joanne Kamens,
- Kazuto Kato,
- Erika Kleiderman,
- Satoshi Kodama,
- John Liddicoat,
- David A. Mackey,
- Ainsley J. Newson,
- Jane Nielsen,
- Jennifer K. Wagner,
- Rebekah E. McWhirter
Affiliations
- Dianne Nicol
- Centre for Law and Genetics, Faculty of Law, University of Tasmania
- Lisa Eckstein
- Centre for Law and Genetics, Faculty of Law, University of Tasmania
- Michael Morrison
- Centre for Health, Law and Emerging Technologies, Nuffield Department of Population Health, University of Oxford
- Jacob S. Sherkow
- Innovation Center for Law and Technology, New York Law School
- Margaret Otlowski
- Centre for Law and Genetics, Faculty of Law, University of Tasmania
- Tess Whitton
- Centre for Law and Genetics, Faculty of Law, University of Tasmania
- Tania Bubela
- Faculty of Health Sciences, Simon Fraser University
- Kathryn P. Burdon
- Menzies Institute for Medical Research, University of Tasmania
- Don Chalmers
- Centre for Law and Genetics, Faculty of Law, University of Tasmania
- Sarah Chan
- Usher Institute for Population Health Sciences and Informatics, University of Edinburgh
- Jac Charlesworth
- Menzies Institute for Medical Research, University of Tasmania
- Christine Critchley
- Department of Statistics, Data Science and Epidemiology, Swinburne University of Technology
- Merlin Crossley
- School of Biotechnology and Biomolecular Sciences, University of New South Wales
- Sheryl de Lacey
- School of Nursing and Midwifery, Flinders University
- Joanne L. Dickinson
- Menzies Institute for Medical Research, University of Tasmania
- Alex W. Hewitt
- Menzies Institute for Medical Research, University of Tasmania
- Joanne Kamens
- Addgene
- Kazuto Kato
- Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University
- Erika Kleiderman
- Centre of Genomics and Policy, Department of Human Genetics, McGill University
- Satoshi Kodama
- Department of Ethic, Graduate School of Letters, Kyoto University
- John Liddicoat
- Faculty of Law, University of Cambridge
- David A. Mackey
- Centre for Ophthalmology and Visual Science, University of Western Australia, Lions Eye Institute
- Ainsley J. Newson
- Sydney Health Ethics, Sydney School of Public Health, University of Sydney
- Jane Nielsen
- Centre for Law and Genetics, Faculty of Law, University of Tasmania
- Jennifer K. Wagner
- Center for Translational Bioethics & Health Care Policy, Geisinger Health System
- Rebekah E. McWhirter
- Centre for Law and Genetics, Faculty of Law, University of Tasmania
- DOI
- https://doi.org/10.1186/s13073-017-0475-4
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 4
Abstract
Editorial summary Genome editing using clustered regularly interspersed short palindromic repeats (CRISPR) and CRISPR-associated proteins offers the potential to facilitate safe and effective treatment of genetic diseases refractory to other types of intervention. Here, we identify some of the major challenges for clinicians, regulators, and human research ethics committees in the clinical translation of CRISPR-mediated somatic cell therapy.
